(Part 3) Adjunctive use of sealants, glues…

 (Continued from here)

The dynamics behind these products’ success: 

  • Significant cost-effectiveness arguments can be made for products that avoid blood transfusions or reduce the quantities of blood transfusion products required. Approximately 8 million patients worldwide would benefit directly from increased usage of hemostats, sealants and glue products to reduce bleeding during cardiovascular, orthopaedic, urologic, and other general surgical procedures. Units of blood cost approximately $180 each; however, the benefit of reducing transfusion requirement goes beyond this simple saving. Often, the real benefit is that appropriate hemostasis reduces the risk of mortality. For example, reducing blood loss during cardiovascular procedures in particular not only prevents the use of large volumes of donated blood (e.g., 5–10 units for dissection of aortic aneurysms) but significantly reduces mortality rates (which can be as high as 30% for aortic aneurysm procedures).
     
  • Adhesion-prevention products have been shown to significantly reduce post-surgical adhesions associated with gynaecological, spinal, cardiovascular and orthopedic procedures. Post-operative adhesions can severely complicate subsequent interventions by making re-entry hazardous, and impeding orientation and visibility, which can lead to damaging the surrounding tissues or vessels. There may also be increased blood loss, and significantly longer operating time required to cut through the adhesions.

 

These dynamics have collectively contributed to the worldwide growth in the market.  Below please find the aggregate worldwide market forecast for these products.

 

Worldwide Growth in the Markets for
Sealants, Glues, Wound Closure and Anti-Adhesion,
2006–2013
 
Sales

Growth

$6,795

 

$7,309

7.6%

$7,860

7.5%

$8,472

7.8%

$9,149

8.0%

$9,921

8.4%

$10,792

8.8%

$11,765

9.0%

 Source: Report #S175, published December 2008, MedMarket Diligence, LLC

Leave a Reply